394 - Determining the Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with High-Risk Sickle Cell Disease (SCD) or Beta Thalassemia Major Following Myeloimmunoablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34+ Selection and T-Cell (CD3) Addback (IND127812)

Edo Schaefer,Jordan Milner,Justine Hung,Janet Ayello,Qiuhu Shi,Julie Talano,Theodore B Moore,Deborah Friedman,Allen J Dozor,Liana Klejmont,Harshini Mahanti,Erin Morris,Ms Sandra Fabricatore,Elizabeth Mintzer,R Paul Guillerman,Allyson Flower,Kenneth R Cooke,Mitchell S Cairo

doi:10.1016/s2666-6367(23)00463-3

394 - Determining the Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with High-Risk Sickle Cell Disease (SCD) or Beta Thalassemia Major Following Myeloimmunoablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34+ Selection and T-Cell (CD3) Addback (IND127812)

Edo Schaefer, Jordan Milner + Show 16 more

https://doi.org/10.1016/s2666-6367(23)00463-3

Copy DOI

Journal: Biology of Blood and Marrow Transplantation

Publication Date: Feb 1, 2023

#High-Risk Sickle Cell Disease #Administration In Children + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

394 - Determining the Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with High-Risk Sickle Cell Disease (SCD) or Beta Thalassemia Major Following Myeloimmunoablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34+ Selection and T-Cell (CD3) Addback (IND127812)

Full Text